Finding new treatment options

Cancer cachexia: Help against muscle loss

Cancer cachexia often occurs in cancer patients in an advanced state. This metabolic wasting syndrome leads to severely reduced muscle mass and fat tissue, which cannot be reversed by nutritional support.

anatomy of human arm muscle
Cancer-related muscle loss can occur in later stages of many cancers

Image source: Henry Vandyke Carter creator QS:P170,Q955620, Gray — musculus coracobrachialis, marked as public domain, details at Wikimedia Commons

Furthermore, muscle regeneration is affected during cancer cachexia due to impaired muscle stem cell function. A problem that also occurs often in the aging process. Cancer cachexia is associated with a poor prognosis for patients, since it weakens patients towards a point that no further therapy, such as chemotherapy or surgery, can be tolerated. So far, this multifactorial syndrome has not been fully understood and effective therapies are still lacking.

The research group "Stem Cells of Skeletal Muscle" lead by Dr. Julia von Maltzahn at the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena, Germany, investigated the extracellular ligand Wnt7a and was able to show its positive influence on muscle mass and muscle stem cells in cancer cachexia independently of the tumor cell type causing cachexia. Wnt7a has already been in focus in muscular dystrophy studies: "It was already known that Wnt7a ameliorates muscular dystrophy", explains von Maltzahn. "We were interested if similar positive effects also occur in cancer cachexia." 

The results of their studies have now been published in the open access journal Molecular Therapy: Oncolytics.

Wnt7a has a dual function in cachectic skeletal muscle: it counteracts muscle wasting and reverts the loss of muscle stem cell functionality.
Source: Magdalena Voll / FLI

The research group was able to show in human skeletal muscle cell lines and in a mouse model that Wnt7a treatment counteracted muscle wasting and improved muscle stem cell differentiation - two major symptoms of cachexia in cancer patients. The extracellular ligand Wnt7a activates the anabolic AKT/mTOR pathway in myofibers and reverts the loss of muscle stem cell functionality. "Our results show that Wnt7a has a dual function in skeletal muscle: it activates an important signaling pathway enhancing muscle mass and drives muscle stem cell expansion in skeletal muscle, which is necessary for regeneration", says Dr. Manuel Schmidt, postdoc in the research group. This makes Wnt7a a promising candidate for the treatment of muscle wasting diseases also in humans, since the protein has the same function in mice and men.

Wnt7a is able to prevent muscle loss in cancer cachexia making it a potential candidate to be used during treatment or surgeries. In addition, the extracellular ligand could be used as a supportive treatment during therapy/surgery. Wnt7a leads to an increase in the stem cell population in the muscle, which supports muscle regeneration after surgery. Following these research results, the researchers are now testing further possible applications.

Source: Leibniz Institute on Aging – Fritz Lipmann Institute (FLI)


Read all latest stories

Related articles


Enhancing T cell response

New targets for cancer vaccines identified

Over the past decade, scientists have been exploring vaccination as a way to help fight cancer. These experimental cancer vaccines are designed to stimulate the body’s own immune system to destroy…


Fossilised findings

Study shows: Even dinosaurs had cancer

A collaboration led by the Royal Ontario Museum (ROM) and McMaster University has led to the discovery and diagnosis of an aggressive malignant bone cancer — an osteosarcoma — for the first time…


Human papillomavirus

HPV vaccination could dramatically reduce head and neck cancers

Vaccinating schoolboys against the potentially deadly human papillomavirus (HPV) could dramatically reduce head and neck cancers in men, according to research involving the University of Strathclyde.…

Related products

Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter